These results indicate that CGM has a high potential for detecting patients with NSTEACS probably at an earlier stage ompared to troponin. Using CGM combined with traditional ECG and troponin may accelerate invasive strategy where needed and help to allocate the resources. Since CGM measures ischemic myocardium, specificity is somewhat lower in this setting, as a remarkable number of patients without NSTE-ACS have established coronary artery disease (CAD). There is an additional benefit for CGM in detecting acute ischemia or relevant stenosis in pts. with normal troponin and ECG.
Laden Sie sich hier die gesamte Studie als PDF herunter: